Palisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial

MT Newswires Live

2025/09/17

Palisade Bio (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.

The study also showed "promising" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.

PALI-2108 also showed a "favorable" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.

The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.

Palisade shares were up more than 4% in recent trading Wednesday.

Price: 0.63, Change: +0.03, Percent Change: +4.58

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2568494530"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568494530\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568494530?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-17 21:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568494530","market":"sg","top_or_hot":-1,"title":"Palisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/PALI\">Palisade Bio</a> (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.</p><p>The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.</p><p>PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.</p><p>The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.</p><p>Palisade shares were up more than 4% in recent trading Wednesday.</p><p>Price: 0.63, Change: +0.03, Percent Change: +4.58</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Palisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPalisade Bio Says Ulcerative Colitis Patients Respond to PALI-2108 Treatment in Phase 1b Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-17 21:53</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/PALI\">Palisade Bio</a> (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.</p><p>The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.</p><p>PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.</p><p>The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.</p><p>Palisade shares were up more than 4% in recent trading Wednesday.</p><p>Price: 0.63, Change: +0.03, Percent Change: +4.58</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PALI","symbol_name":"Palisade Bio Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568494530","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568494530","pubTimestamp":1758117195,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Palisade Bio  said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.Palisade shares were up more than 4% in recent trading Wednesday.Price: 0.63, Change: +0.03, Percent Change: +4.58","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PALI":"Palisade Bio Inc.","BK4007":"制药","BK4139":"生物科技"},"translate_title":"Palisade Bio称溃疡性结肠炎患者在1b期试验中对PALI-2108治疗有反应","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PALI":1.5},"content_text":"Palisade Bio (PALI) said Wednesday that a phase 1b trial of its investigational drug PALI-2108 in ulcerative colitis showed 100% clinical response, with all five patients responding to treatment.The study also showed \"promising\" efficacy data, with two of the five patients achieving clinical remission after seven days based on US Food and Drug Administration-defined endpoints, the company said.PALI-2108 also showed a \"favorable\" safety profile and support anti-fibrotic activity, expanding development potential into fibrostenotic Crohn's disease, Palisade said.The company said it expects to begin patient dosing in a phase 1b trial in fibrostenotic Crohn's disease within the year and targets to file in H1 of 2026 an investigational new drug application for a phase 2 trial.Palisade shares were up more than 4% in recent trading Wednesday.Price: 0.63, Change: +0.03, Percent Change: +4.58","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}